EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 08/05/20
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®GlobeNewsWire • 08/04/20
EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call InformationGlobeNewsWire • 07/29/20
EyePoint Pharmaceuticals Presents Data Supporting YUTIQ® at the American Society of Retina Specialists (ASRS) Virtual Annual MeetingGlobeNewsWire • 07/27/20
EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D.GlobeNewsWire • 07/13/20
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/06/20
EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations UpdateGlobeNewsWire • 04/01/20
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/05/20
EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®GlobeNewsWire • 03/02/20
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewsWire • 02/21/20
EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein OcclusionGlobeNewsWire • 02/03/20
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and TaiwanGlobeNewsWire • 01/27/20